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Abstract
Diethylenetriaminepentaacetic acid (DTPA) is an effective decorporation agent to facilitate the
elimination of radionuclides from the body, but its permeability-limited oral bioavailability limits
its utility in mass-casualty emergencies. To overcome this limitation, a prodrug strategy using the
penta-ethyl ester form of DTPA is under investigation. Pharmacokinetic and biodistribution
studies were conducted in rats by orally administering [14C]DTPA penta-ethyl ester, and this
prodrug and its hydrolysis products were analyzed as a single entity. Compared to a previous
reporting of intravenously administered DTPA, the oral administration of this prodrug resulted in
a sustained plasma concentration profile with higher plasma exposure and lower clearance. An
assessment of the urine composition revealed that the bioactivation was extensive but incomplete,
with no detectable levels of the penta- or tetra-ester forms. Tissue distribution at 12 h was limited,
with approximately 73% of the administered dose being associated with the gastrointestinal tract.
In the efficacy study, rats were exposed to aerosols of 241Am nitrate before receiving a single oral
treatment of the prodrug. The urinary excretion of 241Am was found to be 19% higher than with
the control. Consistent with prior reports of DTPA, the prodrug was most effective when the
treatment delays were minimized.
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INTRODUCTION
Americium-241 is a transuranic radionuclide that is found most abundantly in spent nuclear
fuel as a byproduct of plutonium processing for the production of nuclear power and nuclear
weapons. Widespread exposure to 241Am can occur by its accidental release from nuclear
facilities or by the detonation of nuclear devices. It can also be spread on a smaller scale by
the illicit detonation of radiological dispersal devices, or “dirty bombs.” Contamination can
occur by inhalation, ingestion, or entry through wounds, and internalized 241Am is
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transported in blood before depositing primarily in the skeleton and liver 1–4. Once
deposition occurs, it is difficult to remove the contaminant from the body as current
treatments have limited efficacy. The potential for chronic exposure to localized radiation
following tissue deposition makes for a hazardous radionuclide that can cause cancer and
other radiation-induced injuries.
Intercepting the 241Am in the blood prior to deposition has been proven to be an effective
treatment approach. The current first-line treatment is diethylenetriaminepentaacetic acid
(DTPA), a chelating agent that is used to facilitate the excretion of internalized
radionuclides, including 241Am 5. The molecular structure of DTPA is provided in Figure 1.
The treatment usually involves the intravenous administration of the trisodium calcium or
zinc salts of DTPA, after which these chelating agents distribute to the extracellular fluids
and are rapidly excreted in urine by glomerular filtration 6,7. DTPA exhibits a high binding
affinity for 241Am with a stability constant of 1026.2 M−1, enabling it to preferentially bind
to the radionuclide in the blood 1. In the absence of DTPA, plasma proteins and other
endogenous ligands in the blood bind to 241Am and facilitate the migration of radionuclide
to the deposition sites 3. DTPA mitigates this risk primarily by capturing the radionuclide
prior to tissue deposition and enhancing its urinary excretion.
As an established decorporation agent, DTPA is maintained in the United States Strategic
National Stockpile (SNS) in case of radiological and nuclear emergencies. Its efficacy
against 241Am contamination has been proven mostly in controlled decorporation studies
with animal models 8,9. Rats and beagles represent the most commonly used animal models,
and 30 µmol kg−1 has been established as the standard human dose. A single IV bolus dose
of DTPA at 30 µmol kg−1 in rats administered one hour after IV contamination with 241Am
citrate resulted in the cumulative 14-day urinary decorporation of approximately 43% of the
injected 241Am, compared to 11% in the control group 10. An analysis of the 241Am
retention in bones, liver, and other tissues confirmed that the DTPA treatment contributed to
the significant reduction in tissue accumulation. Similar beneficial effects have been
demonstrated with DTPA in beagles following the same weight-normalized dose. The
efficacy of DTPA is also evident in humans, most notably in the aftermath of the Hanford
americium accident 11. However, the human subjects were victims of accidental
contamination and are not part of controlled studies; thus, the therapeutic effects are not
fully characterized.
Despite the supply of DTPA in the SNS, the growing concerns of nuclear terrorism and
nuclear accidents in recent years have renewed the interest in the development of new or
improved radionuclide decorporation agents 6. One of the major limitations of DTPA is its
need to be administered by intravenous injection or inhalation. Such treatments require
skilled medical personnel for administration, and in emergency situations involving mass-
casualties, the product is not conducive to rapid distribution and self-administration. DTPA
is proven to be most effective when the treatment commences soon after contamination;
delaying the treatment can significantly reduce the overall efficacy, which can only be
compensated partially by repeated treatments over time 12,13. An orally administered dosage
form can alleviate these limitations. However, the oral absorption of DTPA is hampered by
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it hydrophilic nature, resulting in permeability-limited absorption 14. Thus, the poor oral
bioavailability of DTPA makes it unsuitable as a product for oral administration.
To improve the oral delivery of DTPA, a prodrug strategy using the penta-ethyl ester form
of DTPA is under investigation. The molecular structure of DTPA penta-ethyl ester is
provided in Figure 1. The esterification of the ionizable carboxylic acids of DTPA renders a
significantly more lipophilic molecule that can overcome permeability-limited absorption. In
contrast to DTPA with a ClogP of −2.7, DTPA penta-ethyl ester has a more favorable ClogP
of 4.7 and experimentally measured logD values of 1.5–2.5 under intestinal pH
conditions 15. DTPA penta-ethyl ester is an oily liquid; thus, the bioavailability is not
solubility-limited despite its hydrophobicity. Once the prodrug overcomes the permeability
barrier of the gut, it is expected that the carboxylic acid esters will undergo chemical and
enzymatic hydrolysis to form DTPA. Despite the need for multiple ester cleavages, this
complex prodrug is expected to be hydrolyzed extensively, given the prevalence of esterases
along the oral absorption pathway 16–18. Moreover, prior in vivo efficacy studies have
already demonstrated the absorption potential of this prodrug, demonstrating enhanced
decorporation of 241Am in rats following intravenous and intramuscular contamination 19.
This work further explored the oral absorption potential of this prodrug by examining its
pharmacokinetics and biodistribution following the oral administration of DTPA penta-ethyl
ester. Additionally, the efficacy of this prodrug was investigated using the inhalation




[14C]DTPA penta-ethyl ester was purchased from American Radiolabeled Chemicals, Inc.
(St. Louis, MO) as a stock solution of 37 kBq µL−1 in ethanol. The 14C-labels were
positioned on the five metabolically stable carbonyl carbon atoms of the DTPA backbone.
The molecule possessed a specific activity of 2.04 MBq µmol−1. Non-radiolabeled DTPA
penta-ethyl ester was synthesized using the procedure reported previously 20.
241Am nitrate was obtained from the US Department of Energy. An aliquot of the stock
solution was dried and reconstituted in 0.25 M nitric acid to produce a contaminating
solution of 7.4 kBq mL−1 with pH 0.74. The solution was used to create the aerosols for
contaminating the rats in the decorporation study.
Protocols for Animal Studies
The pharmacokinetic and biodistribution studies were conducted in accordance with
protocols approved by the Institutional Animal Care and Use Committee (IACUC) at the
University of North Carolina at Chapel Hill. The decorporation study was approved by the
IACUC at Lovelace Respiratory Research Institute, conducted in facilities accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care International, and
carried out in compliance with the Guide for the Care and Use of Laboratory Animals 21.
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The pharmacokinetics of DTPA penta-ethyl ester and its metabolites were evaluated
following a single, oral dose of [14C]DTPA penta-ethyl ester in female Sprague Dawley rats
(Charles River, Morrisville, NC). Four jugular vein catheterized rats were orally
administered by gavage with a DTPA penta-ethyl ester dose of 187 µmol kg−1 and 14.8
MBq kg−1. A mixture of radiolabeled and non-radiolabeled DTPA penta-ethyl ester was
used to achieve these target doses. The dosing solutions were prepared in a vehicle of pH 4,
25 mM citrate buffer and administered as a solution at a volume of 5 mL kg−1. The rats were
fasted for 6 h prior to dosing and housed in individual metabolic cages for the duration of
the study. Food was presented 4 h after dosing while water was made freely accessible
throughout the study.
The study was carried out for 24 h after administration, at which time the rats were
euthanized. Blood and urine were collected at 1, 2, 4, 8, 12, and 24 h during the in-life phase
of the study. Blood was obtained via the jugular vein catheters and immediately transferred
to collection tubes containing sodium fluoride and potassium oxalate22. Upon blood
collection, the tubes were inverted several times before centrifuging at 3500 RPM for 5 min
to isolate the plasma fraction. For assay, aliquots of plasma and urine were added directly to
10 mL of scintillation cocktail (Ultima Gold, Perkin Elmer, Waltham, MA) and analyzed by
liquid scintillation counting (LSC; Tri-Carb 3110 TR, Perkin Elmer). The LSC data were
corrected for quenching using an external standard.
The LSC data were used to construct profiles for plasma and urine concentrations of 14C
during the study. Since the LSC assay cannot discriminate between the various ethyl esters
of DTPA, all 14C-labeled molecules were treated as a single entity for the pharmacokinetic
and urinary excretion analyses. As DTPA undergoes minimal metabolism 7, the 14C-labeled
molecules were considered to be DTPA or its esterified form. The pharmacokinetic
parameters were calculated by non-compartmental analysis using linear trapezoidal
calculations (Phoenix WinNonlin, Pharsight, Cary, NC).
In a follow-up pharmacokinetic study, the urine composition was evaluated in an attempt to
characterize the extent of in vivo hydrolysis of the prodrug. The study was conducted using
6 rats with the same treatment doses as described previously. Urine samples were collected
at 2, 4, 6, 8, 12, and 24 h after oral administration, and the samples were diluted with an
equal volume of acetonitrile immediately upon collection and stored on ice until analysis to
inhibit post-collection hydrolysis of the ester groups. During preliminary evaluations, this
method was determined to stabilize the esters sufficiently to allow for analysis. The samples
were analyzed by HPLC (Prominence UFLC, Shimadzu, Columbia, MD) with a flow-
through radiochemical detector (Radiomatic 650TR, Perkin Elmer). The HPLC system was
equipped with an Alltima C18 (150 × 2.1 mm ID, 5 µm; Grace Discovery Sciences,
Deerfield, IL) column operating in a 40 °C oven, and the chromatographic separation was
performed at flow rate of 0.25 mL min−1 using mobile phases of 0.1% trifluoroacetic acid in
water (A) and 0.1% trifluoroacetic acid in acetonitrile (B). The mobile phase composition
(A:B) followed a linear gradient from 95:5 to 5:95 over 15 min, followed by an isocratic
phase of 5:95 for 5 min. Following the gradient separation, the eluent passed through the in-
line radiochemical detector, where it was diluted with 5× volume of flow scintillation
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cocktail (Ultima M, Perkin Elmer). Detection and quantification occurred in a 120 µL flow
cell using standard measurement parameters for 14C. The separation method was developed
during preliminary work using MS detection to identify the various esters.
Biodistribution
A biodistribution study was designed to examine the tissue distribution of 14C following the
oral administration of [14C]DPTA penta-ethyl ester. Six female Sprague Dawley rats were
monitored in the study using the same treatment conditions as in the pharmacokinetic
studies. Urine and feces were collected every 4 h during the in-life phase. Euthanasia was
performed 12 h after the administration of the prodrug by overdosing with isofluorane, at
which time the whole blood, stomach, small intestines, cecum, colon, mesentery, liver,
kidneys were collected and weighed. Preliminary studies confirmed these to be the target
organs of accumulation. The urine and plasma (isolated from whole blood) were processed
and analyzed in the same manner as described above.
The solid tissues, including feces, were diluted with a 1:1 mixture of acetonitrile and pH 4,
25 mM citrate buffer and homogenized in polycarbonate vials containing steel grinding
balls. The homogenization was performed by shaking the vials on the high throughput
homogenizer (PowerGen, Thermo Fisher Scientific, Waltham, MA) for 5–8 min at high
speeds. Approximately 200 mg of each homogenate was sampled and combined with 1 mL
of Solvable (Perkin Elmer) and heated in an oven at 60 °C for 1–3 h until digestion was
visibly complete. Once the samples were cooled, hydrogen peroxide (30% in water) was
added in two aliquots of 100 µL to de-colorize the sample. The samples were returned to the
60 °C oven for an additional 1 hour. After cooling, each sample was diluted with 10 mL of
scintillation cocktail and analyzed by LSC. The radioactivity measured in each sample was
weight-corrected to determine the total radioactivity in each whole tissue.
Decorporation Study
The treatment effects of orally administered DTPA penta-ethyl ester were evaluated by
examining the decorporation of 241Am in F344 rats (Charles River). The rats were exposed
by nose-only inhalation to aerosols of 241Am nitrate. The aerosols were produced with a
Hospitec nebulizer and passed through a tube furnace to dry the particles before entering the
small animal, nose-only exposure chamber (In-Tox Products, Moriarty, NM). The
administered aerosol had a measured 241Am concentration of 34.6 kBq L−1 and particle size
of 0.61 µm activity median aerodynamic diameter with a geometric standard deviation of
1.66 based on cascade impaction measurements. The animals were exposed to the aerosol
for 10 min.
A total of 21 male and 21 female rats were contaminated and divided into seven study
groups: four treatment groups and three control groups. The treatment groups were orally
administered by gavage with a 374 µmol kg−1 dose of DTPA penta-ethyl ester at 1 hour, 1
day, 5 days, or 14 days after 241Am contamination. The DTPA penta-ethyl ester was
formulated as a solution in a vehicle of medium-chain triglyceride at a 20% (w/w)
concentration. The dosing solution was administered at a volume of 1 mL kg−1. Similarly,
the control groups were administered with 1 mL kg−1 medium-chain triglyceride vehicle at 1
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day, 5 days, or 14 days after 241Am contamination. The rats were housed in metabolic cages
for the duration of the study with daily urine and feces collection. Food and water were
freely accessible for the duration of the study.
The rats were euthanized at 7 or 8 days post-treatment and necropsy was performed to
determine the retention of 241Am in various tissues. The lungs, trachea, tracheobronchial
lymph nodes (TBLN), liver, spleen, kidneys, gastrointestinal tract (esophagus, stomach,
upper and lower intestines), testes/ovaries, quadriceps, femurs, and soft tissue remains were
collected. All tissue samples, except pelt and carcass, were analyzed directly by gamma
scintillation counting (2480 Wizard2 Gamma Counter, Perkin Elmer) for the 59.5 keV
photons emitted by 241Am. The pelt and carcass were processed by high temperature ashing
(72 h temperature cycles, up to 550 °C) and concentrated nitric acid treatments before
gamma scintillation counting. The 241Am retained in total muscle was calculated by
measuring the concentration of 241Am in the quadriceps and using it to scale to total muscle.
The 241Am concentration in the quadriceps was assumed to be representative of the total
muscle, and for the scaling, 0.59 was used as the muscle fraction of the body mass of a
rat 24. The amount of 241Am in the total muscle was subsequently subtracted from the
total 241Am recovered in carcass and the amount of 241Am measured in the femurs were
added to determine the total 241Am retained in the skeleton. The amount of 241Am in each
tissue was calculated as a fraction of the total 241Am recovered from each rat. Analyses for
statistical differences to assess treatment effects were performed by one-way ANOVA using
JMP 10.0 (SAS Institute, Cary, NC).
RESULTS
Pharmacokinetics
Plasma and urine concentration profiles for 14C were constructed with the LSC data from
the pharmacokinetic study. The plasma concentration profile, shown in Figure 2, exhibits an
absorption phase that achieves an average maximum plasma level (Tmax) at approximately 8
h after dosing. Even after 24 h, elevated levels of the 14C remained in the systemic
circulation. The systemic exposure (AUC0-∞) following an oral dose of 187 µmol kg−1 was
calculated to be 974 h nmol mL−1 by non-compartmental analysis.
The cumulative urinary excretion profile in Figure 3 shows the excretion of 14C over the 24
h period. The cumulative excretion over this period equates to approximately 33% of the
administered dose. Since this quantity does not entirely account for the fraction of the dose
that was distributed to tissues or excreted in feces, it can be assumed that the absorbed
fraction is likely greater than 33%. Furthermore, from Figure 4, the AUC and urinary
excretion within the same sampling intervals show a linear correlation (R2 = 0.877). From
the slope of the linear regression, the renal clearance was estimated to be 0.025 L h−1.
A second pharmacokinetic study was conducted to characterize the extent of bioactivation of
[14C]DTPA penta-ethyl ester by measuring the urine composition using HPLC with
radiochemical detection. The prevalence of esterases along the oral absorption pathway and
the absence of metabolism for DTPA suggest that any in vivo modifications to the prodrug
should be associated with the hydrolysis of the ester groups. The various DTPA esters that
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were measured in the urine are summarized in Figure 5. The chromatographic analysis of the
urine revealed the complete metabolism of the penta-ester form as none was detected.
Likewise, the tetra-ester form was also not detectable in uine. The analysis revealed that the
bioactivation of DTPA penta-ethyl ester was extensive but incomplete. DTPA tri-ethyl ester
represented the most abundant intermediate at all time points, and DTPA was the second
most abundant. After 24 h, DTPA tri-ethyl ester and DTPA made up 33% and 30% of the
total 14C in urine, respectively. These corresponded to 11% and 10% of the administered
prodrug dose, respectively. The mono- and di-ester forms collectively accounted for the
remaining third of the 14C detected in urine.
Biodistribution
The tissue distribution of 14C was assessed 12 h following the oral administration of
[14C]DTPA penta-ethyl ester. The results are summarized in Table 1. Tissue analysis
determined that approximately 73% of the administered 14C was associated with the
gastrointestinal tract after 12 h. Of this, 29% was found to be associated with the stomach,
suggesting that prolonged gastric retention or gastric secretion may have contributed to
incomplete absorption. The slow release of the prodrug from the stomach may have
contributed to a prolonged duration of absorption, resulting in the sustained plasma profile
that was observed in the pharmacokinetic study. In addition to the stomach, high levels
of 14C were measured in the caecum and colon, representing approximately 22% and 18%
of the administered dose, respectively. Interestingly, despite the high levels in the stomach
and colon, the small intestine contained the lowest levels along the gastrointestinal tract,
accounting for only 3% of the administered dose. Meanwhile, fecal excretion was negligible.
Of the tissues that do not make up the gastrointestinal tract, the liver exhibited the
highest 14C content. However, it contained less than 1% of the administered dose.
Approximately 20% of the administered dose was excreted in the urine, consistent with
cumulative recovery at 12 h from the pharmacokinetic study. Despite the high excretion
of 14C in the urine, the kidney contained negligible amounts. Collectively, a total of 90–
110% of the administered 14C was recovered from each rat. This suggests that negligible
amounts of DTPA penta-ethyl ester and its hydrolysis products distributed to the remainder
of the carcass.
Decorporation
Significant therapeutic effects were observed in rats treated with orally administered DTPA
penta-ethyl ester following inhalation exposure to 241Am. The tissue distribution of 241Am
following the various treatments is provided in Table 2. The treatment groups recovered
21.7–24.6 kBq of inhaled 241Am from individual rats, and these recovery values were used
to determine the fraction of 241Am that were retained in the various tissues. Comparison of
the DTPA penta-ethyl ester treatment groups to the corresponding control groups revealed
that the prodrug significantly reduced the accumulation of 241Am in certain tissues. This
decorporation effect was particularly evident in the liver, lungs, and bone, tissues that are
known to be associated with 241Am accumulation. In the case of a 1-hour delay, the
improvements corresponded to 11- and 4-fold reduction in the liver and lungs, respectively
(p < 0.01). At least 2-fold reductions were observed in the bone, gastrointestinal tract,
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kidneys, muscle, soft tissues, and spleen (p < 0.05). Moreover, the treatment was most
effective when the treatment delays were minimized. The apparent high fecal excretion in all
treatment groups was attributed to the mucociliary clearance of 241Am as a consequence of
the inhalation delivery.
The effects of DTPA penta-ethyl ester in promoting the excretion of 241Am were also
clearly evident in the urine data. The daily urinary excretion profiles in Figure 6 show the
effects of the prodrug when the treatment was administered 1 h after contamination. The
treatment effects were most prominent during the first 3 days after treatment. During this
period, the prodrug facilitated the excretion of nearly 18% of the inhaled 241Am,
representing nearly 96% of the cumulative excreted total. Over the 8-day duration, a total of
19% of the inhaled 241Am was excreted, corresponding to a nearly 30-fold improvement
compared to the control (p < 0.001). When treatment delays were extended, the overall
decorporation effects were reduced. The effects of treatment delay on decorporation appear
in the cumulative excretion profiles of Figure 7. The profiles show that a 2-week delay in
treatment reduced the cumulative excretion of 241Am by approximately 5-fold compared to
a 1-hour delay (p < 0.001). Even so, the treatment facilitated the total decorporation of
approximately 4% of the inhaled 241Am, a significant improvement over the control (p <
0.01). The prodrug was most effective when the treatment delays were minimized,
consistent with observations previously reported for DTPA.
DISCUSSION
In order to overcome the oral delivery challenges of DTPA, the penta-ethyl ester prodrug of
DTPA was designed with the intent to increase the lipophilicity of DTPA. Previously
reported physicochemical properties of this prodrug revealed that it has significantly higher
lipophilicity than DTPA and thus, promising potential for oral delivery 15. The in vivo
studies of this work confirmed this absorption potential, demonstrating that at least 33% of
the administered dose was orally absorbed over 24 h based on the urinary excretion data
alone. The extent of absorption is significantly higher than orally administered DTPA,
which has a reported bioavailability of 3% 14.
The improved oral delivery potential with DTPA penta-ethyl ester is further evident when
the pharmacokinetic parameters of the prodrug and DTPA are compared. Following an oral,
187 µmol kg−1 dose of the prodrug, DTPA penta-ethyl ester and its hydrolysis products
contributed to an AUC0-∞ and renal clearance of 974 h nmol mL−1 and 0.025 L h−1,
respectively. In contrast, intravenously administered DTPA at a dose of 29.4 µmol kg−1
resulted in an AUC0-∞ and clearance of 7.1 h nmol mL−1 and 0.25 L h−1, respectively 24.
Even with dose-normalization to account for the difference in administered doses, the
prodrug exhibited 20-fold higher plasma exposure and a 10-fold lower clearance than
DTPA. The significant difference in these pharmacokinetic parameters suggests that the
pharmacological activity of the prodrug treatment is likely to be significantly different from
DTPA.
While the rate and extent of bioactivation of DTPA penta-ethyl ester remains unknown, the
pharmacokinetic behavior following the administration of this prodrug could be favorable
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for improving the radionuclide decorporation effects over DTPA. One limitation of DTPA
for therapeutic efficacy may be its rapid elimination kinetics in relation to the biokinetics of
radionuclides. The primary site of DTPA chelation is in the blood and extracellular fluid
(ECF), and while the rapid onset and elimination following a bolus injection of DTPA may
be advantageous for facilitating the rapid excretion of contaminants, the chelating agent
must be present in the blood and ECF at the appropriate time and at sufficient levels to
intercept the contaminant. Thus, it is important for the pharmacokinetics of DTPA to align
with the biokinetics of the contaminant. However, not all contamination scenarios manifest
themselves in immediate uptake of the contaminant into the systemic circulation. The rate of
systemic entry depends on the route of contamination and the properties of the radionuclide,
including solubility, charge, and chemical form 25,26. Incorporation via inhalation and
wound are considered to be the two of the most probable routes of radionuclide
contamination and are characterized as exhibiting slow or protracted entry of the
contaminant into the bloodstream 9,27,28. Unless frequent injections or continuous infusion
of DTPA are administered, its rapid elimination could quickly deplete the available DTPA
in the blood and allow for only a limited duration of efficacy. Accordingly, alternative
delivery methods with both DTPA and DTPA penta-ethyl ester have been proposed 24,29,30.
An orally bioavailable chelating agent that can provide extended durations of efficacy may
be better suited for radionuclide decorporation in a real-life contamination scenario.
Interestingly, the plasma concentration of 14C following the oral administration of
[14C]DTPA penta-ethyl ester appears to exhibit a sustained profile. The long residence time
of the prodrug and its DTPA intermediates in the plasma is in stark contrast to DTPA, which
is known to be eliminated very rapidly with a half life of 0.53 h following an intravenous
injection 24. A possible explanation for the sustained profile is that the prodrug is absorbed
over an extended duration contributing to a prolonged influx of 14C into the systemic
circulation. Based on the high retention of 14C in the stomach from the biodistribution study,
the stomach may be acting as a depot. As the formulation and the administered volume were
not unusual for biodistribution studies, these do not appear to be factors in the observed
prolonged gastric retention. Previous in vitro evaluations suggested that the prodrug is
sufficiently stable against premature chemical hydrolysis in the acidic environment of the
stomach15. Alternatively, the prodrug may be metabolized in the epithelium, entrapping the
DTPA intermediates and slowing its transport to the systemic circulation. Another
possibility for the sustained plasma levels may be the result of altered elimination kinetics, a
potential consequence of the incomplete conversion of DTPA penta-ethyl ester to DTPA in
the plasma. The DTPA intermediates are more lipophilic than DTPA and may have a higher
tendency to bind to plasma proteins resulting in lower renal clearance. The intermediates
may also distribute more readily to the tissues, further reducing the elimination rate. The
combination of longer absorption, larger volumes of distribution and slower elimination may
contribute to producing a sustained plasma concentration profile as the one observed with
the prodrug treatment.
An analysis of the urine composition confirmed that the bioactivation of DTPA penta-ethyl
ester was extensive but incomplete. Preliminary in vitro stability evaluations of DTPA
penta-ethyl ester in rat plasma revealed that hydrolysis is very rapid, with complete loss of
the penta- and tetra-ester forms occurring within 10 min (data not shown). Thus, it was
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considered improbable for any absorbed prodrug to enter the plasma and avoid metabolism
before excretion. Unfortunately, an attempt to characterize the composition in plasma was
unsuccessful. As part of the pharmacokinetic study, plasma samples were diluted with
acetonitrile and analyzed by HPLC using the same methods as described for urine. This
sample processing method appeared to sufficiently stabilize the DTPA esters during
preliminary in vitro evaluations; however, the data from the in vivo study indicated a nearly
complete conversion to DTPA. Since the in vivo study required additional time to isolate the
plasma from whole blood before the sample could be stabilized, it is believed that the multi-
ester intermediates may have hydrolyzed during this period. Under these circumstances, the
composition in the urine was considered to provide the most reliable representation of the
extent of bioactivation.
Despite the incomplete bioactivation of DTPA penta-ethyl ester to DTPA, the in vivo
decorporation study demonstrated the therapeutic potential of the prodrug. The inhalation
route of contamination was chosen in this decorporation study to mimic the route of
contamination that may occur in a real-life scenario. Contamination with 241Am nitrate is a
realistic hazard and the chemical complex is a moderately soluble form that can slowly
release from the lung and into the systemic circulation 9,28,31. Administering the prodrug 1 h
after contamination resulted in an 11-fold decrease in liver accumulation compared to the
control treatment in this study. In contrast, as previously reported, administering the same
treatment with the same treatment delay after intravenous and intramuscular contamination
reduced the accumulation of 241Am in liver by less than 3-fold compared to the
corresponding control treatments 19. Although the extent of actual decorporation may differ
due to differences in the amount of accessible contaminant, the relative therapeutic effects in
the context of the corresponding controls emphasize the importance of understanding the
distribution kinetics of the contaminant to select the appropriate type of treatment.
The observed efficacy in spite of the incomplete hydrolysis of DTPA penta-ethyl ester from
urine data suggests that the overall decorporation may be an additive effect produced by the
contributions from the various DTPA intermediates. Even with incomplete bioactivation, the
DTPA intermediates possess multiple coordination sites to chelate metals in the blood. This
potential is exemplified in the established relationship between the number of coordination
sites on a chelating agent and the binding of 241Am 32. The tri-ethyl ester of DTPA, with
five coordination sites, represents the DTPA intermediate in the urine with the fewest
number of coordination sites. According to this relationship, it may still possess a high
affinity for 241Am with a stability constant of approximately 1015 M−1. The other
intermediates have a greater number of coordination sites and would likely have greater
affinities for 241Am. Assuming that this relationship applies for all DTPA intermediates,
complete bioactivation of DTPA penta-ethyl ester to DTPA may not be necessary to
effectively chelate 241Am in the blood.
In addition to intercepting the radionuclides in the blood, extraction of contaminants from
tissues is another means to facilitate decorporation. However, the conventional DTPA
treatment is challenged by its limited ability to cross cell membranes and facilitate the
excretion of contaminants from the intracellular compartment of tissues 33. A complete
conversion of DTPA penta-ethyl ester to DTPA may not be favorable to facilitate the
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removal of deposited radionuclides. Partially hydrolyzed forms of the prodrug are more
lipophilic than DTPA and may have the potential advantage to access the intracellular space,
thereby enhancing the extraction of radionuclides from the deposition sites. The penta-ethyl
ester of DTPA was previously administered by intraperitoneal injection to explore this
decorporation mechanism and was proven to facilitate intracellular decorporation
of 239Pu 33. This type of mechanism may be particularly advantageous when the treatment
following contamination is delayed and extensive tissue deposition has already occurred.
This effect appears to be evident in the decorporation study reported here which showed that
the 241Am retention in the primary deposition sites of lung, liver, and bone were reduced
significantly even after a 14-day delay in the treatment with the prodrug. With an
intracellular decorporation mechanism, repeated administration of this prodrug may further
add to the therapeutic effects by extending the ability to extract the radioactive contaminants
from the deposition sites.
The DTPA penta-ethyl ester treatments were most efficacious when the treatment delays
after contamination were minimized. An extension of the treatment delay from 1 h to 1 day
resulted a 2-fold reduction in 241Am decorporation. The decrease in the therapeutic effect
became less apparent with longer treatment delays. This overall trend is consistent with the
effects observed after conventional DTPA treatments, which relies primarily on intercepting
the radionuclides before tissue deposition. Even though the incomplete bioactivation of the
prodrug may enhance the intracellular decorporation of radionuclides, capturing the
contaminants before deposition appears to be the most effective mechanism for
decorporation. The diminished effects after longer treatment delays with this prodrug reflect
the need to still provide urgent treatment to victims of contamination.
CONCLUSIONS
The pharmacokinetics, biodistribution and efficacy of orally administered DTPA penta-ethyl
ester were investigated in rats. A single dose treatment in the pharmacokinetics study
revealed that greater than 33% of the administered dose was absorbed based on urinary
excretion data alone. From the urine composition, the bioactivation was determined to be
extensive but incomplete. The plasma concentration profile showed elevated plasma levels
of the prodrug and its hydrolysis products for 24 h. The biodistribution study showed that
the prodrug and the intermediates were primarily retained in the gastrointestinal tract with
limited distribution to other tissues after 12 h. In the efficacy study, a single dose treatment
of DTPA penta-ethyl ester administered after contamination enhanced the decorporation of
inhaled 241Am by as much as 15-fold compared to the control treatment. Consistent with
prior reports of DTPA, the therapeutic effects of the prodrug were maximized when the
treatment delays were minimized. Overall, DTPA penta-ethyl ester exhibited promising
pharmacokinetic and therapeutic behavior as an orally administered radionuclide
decorporation agent.
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Structures of DTPA and DTPA penta-ethyl ester
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Plasma concentration of 14C in individual rats from the oral administration of [14C]DTPA penta-ethyl ester
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Cumulative urinary excretion of 14C from the oral administration of [14C]DTPA penta-ethyl ester (error bars represent 95% CI
about the mean)
Sueda et al. Page 16























Correlation between AUC within plasma sampling intervals and urinary excretion within urine collection intervals following the
oral administration of [14C]DTPA penta-ethyl ester
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Composition of the DTPA penta-ethyl ester bioactivation products in urine (error bars represent 95% CI about the mean): DTPA
( ); DTPA mono-ethyl ester ( ); DTPA di-ethyl ester ( ); DTPA tri-ethyl ester ( ); DTPA tetra-ethyl ester and DTPA penta-
ethyl ester (not detected)
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Daily urinary excretion of 241Am (error bars represent 95% CI about the mean): 1-hour treatment delay with prodrug ( ) and
control ( )
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Cumulative urinary excretion of 241Am by treatment group (error bars represent 95% CI about the mean): 1-hour treatment
delay ( ); 1-day treatment delay ( ); 5-day treatment delay ( ); 14-day treatment delay ( ); control ( ). Statistical
difference between treatment groups determined on the cumulative total: * p < 0.05, ** p < 0.01, *** p < 0.001
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Tables 1
Tissue distribution of 14C following the oral administration of [14C]DTPA penta-ethyl ester
Tissue Recovery (%, mean ± 95% CI)
Caecum 22.2 ± 8.7
Colon 18.5 ± 7.1
Feces 0.68 ± 1.13
Kidneys 0.147 ± 0.057
Liver 0.759 ± 0.152
Mesentery 0.039 ± 0.008
Small intestines 3.33 ± 0.94
Spleen 0.010 ± 0.007
Stomach 28.9 ± 10.5
Urine 20.5 ± 5.1
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